Supplementary Figure S17 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression

Chuandong Geng; Man-Chao Zhang; Ganiraju C. Manyam; Jody Vykoukal; Johannes F. Fahrmann; Shan Peng; Cheng Wu; Sanghee Park; Shakuntala Kondraganti; Daoqi Wang; Brian D. Robinson; Massimo Loda; Christopher E. Barbieri; Timothy A. Yap; Paul G. Corn; Samir Hanash; Bradley M. Broom; Patrick G. Pilié; Timothy C. Thompson

doi:10.1158/1078-0432.27034324

Abstract

Supplementary Fig. S17. Original unedited IB images for representative Western blots experiments (n-2) used in Figure 4E right panels (RM-1-BM-EV/ SPOPmuts).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Geng et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875226ea https://doi.org/10.1158/1078-0432.27034324

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S17 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression

Abstract

Discussion

Cite This Study

Supplementary Figure S17 from SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers